Corticosteroid-Resistant Sarcoid Choroidal Granuloma Presenting With Optic Disc Edema

A54-year-old man with untreated psoriatic arthritis was referred for evaluation of optic disc edema in his right eye. He was found to have an associated peripapillary choroidal granuloma, verified by enhanced depth imaging optical coherence tomography (EDI-OCT)

Incident Ocular Inflammation After COVID-19 Infection in a US Veteran Population

To investigate whether COVID-19 infection is a risk factor for incident ocular inflammatory disease. Retrospective case-crossover study. The US Veterans Health Administration Corporate Data Warehouse was used to identify patients with positive COVID-19 testing and incident ocular inflammatory disease between March 2020 and May 2022. The timing of incident ocular inflammation and COVID-19 testing was assessed for each participant to determine whether positive COVID-19 testing occurred 0–60 days prior to incident ocular inflammation diagnosis (risk period) or 15–75 days after incident ocular inflammation diagnosis (control period). The main outcome measure was the odds of positive COVID-19 testing in the risk period versus control period. Of the 1006 patients with incident ocular inflammation and a positive COVID-19 test in the study period, the age mean ± standard deviation was 62.6 ± 9.8 years and 840 (83%) were male. The odds of COVID-19 exposure was higher in the risk than control period (odds ratio [OR], 1.56; 95% confidence interval [CI], 1.04–2.36; P = 0.03). Ocular inflammation was more likely to be bilateral in the risk period (OR, 3.97; 95% CI, 1.01–23.01; P = 0.03). Other ocular features and demographic characteristics were similar in the risk and control periods. Most cases of ocular inflammation were quiescent at the most recent eye examination. Incident ocular inflammation is associated with COVID-19 infection, but the increased risk is small, and the ocular inflammation is typically acute.</p

Uveitis reactivation following recombinant zoster vaccination

Purpose: Describe three cases of uveitis reactivation following immunization with recombinant zoster vaccine (RZV). Observations: One patient developed reactivation of previously controlled multifocal choroiditis within one week of receiving RZV, requiring treatment with systemic corticosteroids. Two patients with previously controlled anterior uveitis developed new anterior segment inflammation after RZV; both were treated with topical corticosteroids and systemic antiviral therapy. Conclusion and importance: Uveitis recurrence is an infrequent but serious potential ocular side effect of recombinant zoster vaccination

Therapeutic Outcomes of Non-Infectious Scleritis Treated with Tumor Necrosis Factor-Alpha Inhibitors

We determine the efficacy of tumor necrosis factor-α (TNF) inhibitors in establishing scleritis quiescence. We conducted a multicenter retrospective chart review of patients with non-infectious scleritis treated with a TNF inhibitor for at least 6 months. The primary endpoint was scleritis quiescence at 6 months. Secondary endpoints included scleritis quiescence at 12 months, TNF inhibitor effects on concurrent doses of systemic corticosteroids and visual acuity outcomes at 6 and 12 months. At 6 months, 82.2% (37/45) of subjects obtained scleritis quiescence with TNF inhibition. At 12 months, 76.2% (32/42) of subjects remained quiescent. Baseline daily corticosteroid use (21.5 ± 21.6 mg) decreased to 5.4 ± 8.3 mg by 6 months (p p p = 0.52). TNF inhibitors are an effective scleritis therapy with significant systemic corticosteroid sparing effect.</p